EHA Scientific Working Groups: Connecting Science and Spreading Knowledge in Hematology by Sonneveld, P. (Pieter)
HEMASPHERE-2020-0063; Total nos of Pages: 3;
HEMASPHERE-2020-0063
Powered by EHA
HemaTopicsEHA Scientific Working Groups: Connecting
Science and Spreading Knowledge in Hematology
Pieter Sonneveld1,2
Correspondence: Pieter Sonneveld (e-mail: p.sonneveld@erasmusmc.nl)1Department of Hematology, Erasmus
MC Cancer Institute, Rotterdam, The
Netherlands
2European Hematology Association
Scientific Working Group Committee,
The Hague, The Netherlands.
PS received honoraria from Amgen,
Celgene/BMS, Janssen, Karyopharm,
SkylineDx.
Copyright © 2020 the Author(s).
Published by Wolters Kluwer Health,
Inc. on behalf of the European
Hematology Association. This is an
open access article distributed under
the terms of the Creative Commons
Attribution-Non Commercial-No
Derivatives License 4.0 (CCBY-NC-
ND), where it is permissible to
download and share the work
provided it is properly cited. The work
cannot be changed in any way or
used commercially without permission
from the journal.
HemaSphere (2020) 4:2(e365)
Received: 11 February 2020 /
Accepted: 18 February 2020
Citation: Sonneveld P. EHA
Scientific Working Groups:
Connecting Science and Spreading
Knowledge in Hematology.
HemaSphere, 2020;4:2. http://dx.doi.
org/10.1097/HS9.0000000000000365Navigating the EHA roadmap
In the European Union, an estimated 80 million people are affected with one of the blood
disorders, which range from cancers to coagulation defects.1 To help explore and manage these
diseases, the European Hematology Association (EHA) Roadmap for European Hematology
Research pinpointed important priorities and needs spanning the different areas of hematology.1
The nine key sections identified within the EHA Roadmap consensus document include normal
hematopoiesis, malignant lymphoid diseases, malignant myeloid diseases, anemias and related
diseases, platelet disorders, blood coagulation and hemostatic disorders, transfusion medicine,
infections in hematology, and hematopoietic stem cell transplantation.1
It is EHA’s ambition to comprehensively represent and reflect the entire spectrum of hematology
research across Europe by supporting and working in synergy with Scientific Working Groups
(SWGs). SWGs are a key tool that enables EHA to connect and collaborate with experts across the
whole range of hematology laid out in the EHA roadmap.Leveraging the power of SWGs
By partnering with the expert researchers and clinicians who are members of the SWGs, EHA
envisages to support science and spread knowledge in basic, translational and clinical research in
hematology across Europe. The key goals of the SWGs are: To initiate and create scientific networks that serve under the umbrella of EHA.
 To collaborate with existing networks in specific hematology areas and connect these with EHA.
 To promote high-quality science within the EHA community and identify new innovative areas
for research. To drive best patient care through the development of guidelines.
 To advise the EHA Board and European Affairs Committee on scientific policies and priorities in
research.
Through its SWGs, EHA is undertaking activities to address current unmet needs in the
hematology arena, define disease areas that warrant extra exploration and focus on new
ambitions, exploring future frontiers in hematology research.
In total, there are currently 24 SWGs covering fields of hematology which are closely aligned
with the nine key sections of the EHA roadmap. Structurally, these SWGs are organized into either
disease-orientated or overarching groups. The topics covered by each of the 2 broad families of
SWG are listed in Figure 1.
Each SWG is represented by an expert Chair and Co-chair, who are both EHAmembers, as well
as an Executive Committee. Annual reports on the activities of each SWG are produced and
published online on the EHA website.
To further support high-quality science, specific slots for SWG sessions are incorporated into the
main EHA Annual Congress program.2 These 1-hour events are designed to showcase state-of-the
art in the specific sector of hematology being focused on by each SWG, and collectively offer
updates on a range of important areas in hematology research.
EHA also organizes dedicated scientific meetings for SWGs which follow an innovative,
interactive format and incorporate the latest insights from leading hematologists in the field. Three
or four of these scientific workshops are organized annually in Europe, with each meeting
attracting between 80 and 150 delegates. In 2019, for instance, 4 EHA-SWG Scientific Meetings1
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Figure 1. European Hematology Association Scientific Working Groups (SWGs) and topics.
HemaTopics HemaTopicswere organized, including the 1st European CAR T-Cell
meeting. Examples of upcoming EHA-SWG scientific meetings
include: The EHA-SWG Scientific Meeting on Mesenchymal Stromal
Cells and Tissue Homeostasis. The 4th edition of this EHA-
SWG Scientific Meeting will span 3 days, during which
participants will enhance their understanding of the key
principles of tissue homeostasis, with a particular focus on
stromal cells. It is organized in collaboration with EHA and the
Mesenchymal Stromal Cells SWG. The EHA-EBMT 2nd European CAR T-Cell Meeting, which
will be held in Sitges (Spain) from 30 January to 1 February
2020. This meeting is jointly organized by the EHA and the
European Society for Blood and Marrow Transplantation
(EBMT).
EachSWGenjoys the freedom topursue its own specific research
programs and initiatives. As the composition and scope of
individual SWGs can prove extremely variable, EHA members
are encouraged to consult the SWG section of the EHA website
(https://ehaweb.org/research/scientific-working-groups/) for a full
update on the range of activities being undertaken by each group.SWGs in action
Key initiatives carried out by EHA have successfully leveraged
the power of SWGs as networks of experts in their respective2fields of hematology. Due directly to the work of SWGs,
important steps forward have been taken with the development
of new clinical guidelines, the establishment of relevant research
collaborations, as well as providing scientific advice for policy
and regulation.
A number of disease-oriented EHA SWGs have been actively
involved in the guideline development process for their respective
fields, helping to drive evidence-based best practice within
hematology. For example, the Thrombocytopenia and Platelet
Function Disorders SWG has prepared and published, with the
support of EHA, consensus recommendations on the initial
diagnostic approach to mild to moderate bleeding disorders,
which remain a difficult group of diseases to definitively diagnose
and effectively treat. This report marks the first step in an EHA
initiative to develop evidence-based guidelines for specific mild
and moderate bleeding disorders.3 Follow-up papers will focus
on von Willebrand disease (VWD), coagulation and fibrinolytic
system disorders and platelet and vascular disorders. EHA also
partners when relevant with other networks and societies, such as
the European Society for Medical Oncology (ESMO), to produce
collaborative guidelines.
Efforts are also ongoing within the overarching SWGs to
develop new guidelines and recommendations in emerging areas
of hematology or key topics that are not yet covered. For
example, the SWG on Aging and Hematology is working to
develop clinical guidance on cardiovascular complications in
older adults undergoing therapy for hematologic malignancies.
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(2020) 4:2 www.hemaspherejournal.comThe Quality of Life SWG is also involved in the creation
and validation of a novel tool for the evaluation of patient-
reported outcomes (PROs) in patients with hematological
malignancies (HM-PRO), which is being translated and will
be available in over 10 international languages by the end of
2019.
Echoing EHA’s central ethos of collaboration and partnership,
SWGs are also actively participating in important initiatives
within the wider hematology landscape. A prime example of this
is the collaboration with the HARMONY Alliance, a public-
private European Network of Excellence whose mission is to
unlock and spread valuable knowledge on hematologic malig-
nancies. From within EHA, the European Research Initiative on
CLL (ERIC), Myelodysplastic Syndromes (MDS), Adult Acute
Lymphoblastic Leukemia (EWALL), Multiple Myeloma (MM),
Acute Myeloid Leukemia (AML) and the EHA Lymphoma
Group SWGs are all working closely with the HARMONY
Alliance to harness and mine big data in order to expedite the
development of improved treatment options for patients with
hematological cancers.Harnessing the opportunity
SWGs provide scientists, researchers and clinicians with the
unprecedented opportunity to assume an active role in shaping
the future research landscape in hematology. By supporting
SWGs, EHA aims to provide a research platform that is accessible
and available to all groups and researchers across the entire EHA
roadmap.3Individuals currently working within hematology - from the
bench to the bedside - are encouraged tobecomeactive participants
in existing SWG networks that reflect their own research and
clinical expertise and interests. SWG membership is open to any
physician and researcher with a professional interest that mirrors
that of the group itself. EHA members can connect with specific
SWGs via the annual EHA congress or through EHA channels like
the website. Membership Application Forms can be downloaded
from the EHA-SWG Procedure and Reports webpage (https://
ehaweb.org/research/scientific-working-groups/procedure-and-
reports/) and submitted to SWGs@ehaweb.org. SWGs also
provide a unique vehicle to drive research into new and emerging
frontiers in hematology.
Through close collaboration and the sharing of knowledge
under the umbrella of EHA, involvement in SWGs offers EHA
members the opportunity to continue to advance and accelerate
hematology research towards a brighter future.References
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